Acorda Therapeutics Performance
| ACORDelisted Stock | USD 16.20 0.40 2.41% |
The firm shows a Beta (market volatility) of 0.58, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Acorda Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Acorda Therapeutics is expected to be smaller as well. Acorda Therapeutics right now shows a risk of 0.0%. Please confirm Acorda Therapeutics semi variance, and the relationship between the treynor ratio and daily balance of power , to decide if Acorda Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Acorda Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Acorda Therapeutics is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 44.4 M |
Acorda |
Acorda Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,620 in Acorda Therapeutics on October 25, 2024 and sell it today you would earn a total of 0.00 from holding Acorda Therapeutics or generate 0.0% return on investment over 90 days. Acorda Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Acorda, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Acorda Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acorda Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Acorda Therapeutics, and traders can use it to determine the average amount a Acorda Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ACOR |
Based on monthly moving average Acorda Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acorda Therapeutics by adding Acorda Therapeutics to a well-diversified portfolio.
Acorda Therapeutics Fundamentals Growth
Acorda Stock prices reflect investors' perceptions of the future prospects and financial health of Acorda Therapeutics, and Acorda Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acorda Stock performance.
| Return On Equity | -0.24 | |||
| Return On Asset | -0.0577 | |||
| Profit Margin | (2.15) % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 161.45 M | |||
| Shares Outstanding | 1.24 M | |||
| Price To Earning | 0.95 X | |||
| Price To Book | 0.05 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 117.63 M | |||
| EBITDA | 8.4 M | |||
| Cash And Equivalents | 20.7 M | |||
| Cash Per Share | 0.85 X | |||
| Total Debt | 190.9 M | |||
| Debt To Equity | 2.56 % | |||
| Book Value Per Share | (127.17) X | |||
| Cash Flow From Operations | (13.98 M) | |||
| Earnings Per Share | (203.57) X | |||
| Total Asset | 117.75 M | |||
| Retained Earnings | (1.19 B) | |||
| Current Asset | 451.32 M | |||
| Current Liabilities | 90.59 M | |||
About Acorda Therapeutics Performance
Assessing Acorda Therapeutics' fundamental ratios provides investors with valuable insights into Acorda Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Acorda Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York. Acorda Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 118 people.Things to note about Acorda Therapeutics performance evaluation
Checking the ongoing alerts about Acorda Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acorda Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acorda Therapeutics is not yet fully synchronised with the market data | |
| Acorda Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 117.63 M. Net Loss for the year was (252.85 M) with profit before overhead, payroll, taxes, and interest of 82.43 M. | |
| Acorda Therapeutics currently holds about 20.7 M in cash with (13.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85. |
- Analyzing Acorda Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acorda Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Acorda Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acorda Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acorda Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acorda Therapeutics' stock. These opinions can provide insight into Acorda Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Acorda Stock
If you are still planning to invest in Acorda Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acorda Therapeutics' history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |